{"id":509195,"date":"2021-07-01T17:17:06","date_gmt":"2021-07-01T21:17:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/"},"modified":"2021-07-01T17:17:06","modified_gmt":"2021-07-01T21:17:06","slug":"shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/","title":{"rendered":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders"},"content":{"rendered":"

<\/p>\n

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders<\/b><\/p>\n

SAN DIEGO & HAYWARD, Calif.–(BUSINESS WIRE<\/a>)–
\nShareholder rights law firm Robbins LLP<\/a> reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain.\n<\/p>\n

\nIf you suffered a loss due to AcelRx Therapeutics, Inc.’s misconduct, click here<\/a>.\n<\/p>\n

AcelRx Therapeutics, Inc. (ACRX) Made Misstatements in Advertising for its Lead Drug Candidate DSUVIA <\/i><\/b><\/p>\n

\nAccording to the complaint, during the relevant period, defendants made false and\/or misleading statements and\/or failed to disclose that: (i) AcelRx had deficient disclosure controls and procedures with respect to its marketing of DSUVIA; (ii) as a result, AcelRx had been making false or misleading claims and representations about the risks and efficacy of DSUVIA in certain advertisements and displays; (iii) this conduct subjected the Company to increased regulatory scrutiny and enforcement; and (iv) as a result, the Company’s public statements were materially false and misleading.\n<\/p>\n

\nOn February 16, 2021, AcelRx disclosed that, on February 11, 2021, the Company received a warning letter from the FDA concerning promotional claims for DSUVIA. Specifically, having “reviewed an ‘SDS Banner Ad’ (banner) (PM-US-DSV-0018) and a tabletop display (PM-US-DSV-0049) (display),” the FDA concluded that “[t]he promotional communications, the banner and display, make false or misleading claims and representations about the risks and efficacy of DSUVIA,” and “[t]hus \u2026 misbrand DSUVIA within the meaning of the Federal Food, Drug and Cosmetic Act (FD&C Act) and make its distribution violative.” The earning letter “request[ed] that AcelRx cease any violations of the FD&C Act” and “submit a written response to th[e] letter within 15 days from the date of receipt.”\n<\/p>\n

\nOn this news, AcelRx’s stock price fell $0.21 per share, or 8.37%, to close at $2.30 per share on February 16, 2021. The stock now trades at around $1.50.\n<\/p>\n

If you purchased shares of<\/i><\/b>AcelRx Therapeutics, Inc. (ACRX) between March 17, 2020 and February 12, 2021, you have until August 9, 2021, to ask the court to appoint you lead plaintiff for the class.<\/i><\/b><\/p>\n

All representation is on a contingency fee basis. Shareholders pay no fees or expenses. <\/i><\/b><\/p>\n

\nContact us to learn more:
\n
Lauren Levi
\n
(800) 350-6003
\n
llevi@robbinsllp.com
\n<\/a>
Shareholder Information Form<\/a><\/p>\n

\nRobbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against AcelRx Therapeutics, Inc. settles or to receive free alerts about companies engaged in wrongdoing, sign up for Stock Watch<\/a> today.\n<\/p>\n

\nAttorney Advertising. Past results do not guarantee a similar outcome.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20210701005923\/en\/<\/a><\/span><\/p>\n

\nLauren Levi
\n
Robbins LLP
\n
5040 Shoreham Place
\n
San Diego, CA 92122
\n
llevi@robbinsllp.com
\n<\/a>
(800) 350-6003
\n
www.robbinsllp.com<\/a><\/p>\n

KEYWORDS:<\/b> United States North America California<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Professional Services<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders SAN DIEGO & HAYWARD, Calif.–(BUSINESS WIRE)– Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. If you suffered a loss due to AcelRx Therapeutics, Inc.’s misconduct, click here. AcelRx Therapeutics, … <\/p>\n

Continue reading “SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509195","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders SAN DIEGO & HAYWARD, Calif.–(BUSINESS WIRE)– Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. If you suffered a loss due to AcelRx Therapeutics, Inc.’s misconduct, click here. AcelRx Therapeutics, … Continue reading "SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T21:17:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders\",\"datePublished\":\"2021-07-01T21:17:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/\"},\"wordCount\":526,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/\",\"name\":\"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2021-07-01T21:17:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk","og_description":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders SAN DIEGO & HAYWARD, Calif.–(BUSINESS WIRE)– Shareholder rights law firm Robbins LLP reminds investors that a class action has been filed on behalf of all purchasers of AcelRx Therapeutics, Inc. (NASDAQ:ACRX) securities between March 17, 2020 and February 12, 2021, against the Company for remedies under the Securities Exchange Act of 1934. AcelRx is a pharmaceutical company that develops and commercializes therapies for the treatment of acute pain. The Company’s lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. If you suffered a loss due to AcelRx Therapeutics, Inc.’s misconduct, click here. AcelRx Therapeutics, … Continue reading \"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T21:17:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders","datePublished":"2021-07-01T21:17:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/"},"wordCount":526,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/","name":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en","datePublished":"2021-07-01T21:17:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20210701005923r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-robbins-llp-reminds-investors-that-acelrx-pharmaceuticals-inc-acrx-is-being-sued-for-misleading-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER ALERT: Robbins LLP Reminds Investors That AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509195","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509195"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509195\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509195"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509195"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509195"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}